AstraZeneca defends Crestor
This article was originally published in The Tan Sheet
Executive Summary
A Circulation article linking Crestor (rosuvastatin) to a higher risk of muscle and kidney toxicity compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca says May 23. The study by Alawai Alsheikh-Ali, Tufts-New England Medical Center, et al., "attempts to draw conclusions that simply cannot be drawn from adverse event reporting data," the firm says. The findings were released in May (1"The Tan Sheet" May 30, 2005, p. 6)...
You may also be interested in...
Circulation Articles Question Crestor, Stress Statin Selection Complexity
Appropriate selection of cholesterol-lowering statins is complicated by determining desirable LDL levels for a patient and comparing side-effect profiles of drugs in the class, an editorial in the May 23 issue of Circulation maintains
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.